In a Phase IIa trial, the injectable drug met all primary and secondary endpoints in affected patients who did not respond to intranasal corticosteroids, Sanofi said in a statement.
Dupilumab is also being tested by the drugmakers against two other allergic conditions - atopic dermatitis and asthma.